Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Shanghai Yizhong Pharmaceutical Co's enterprise value is ¥8,193.3 Mil.
Shanghai Yizhong Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥78.4 Mil. Therefore, Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA for today is 104.57.
SHSE:688091'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -622.37 Med: 82.8 Max: 2682.38
Current: 104.57
During the past 8 years, the highest EV-to-EBITDA of Shanghai Yizhong Pharmaceutical Co was 2682.38. The lowest was -622.37. And the median was 82.80.
SHSE:688091's EV-to-EBITDA is ranked worse than 96.51% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs SHSE:688091: 104.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Yizhong Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Shanghai Yizhong Pharmaceutical Co's share price for today is ¥41.65.
Shanghai Yizhong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.336.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Yizhong Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA falls into.
Shanghai Yizhong Pharmaceutical Co's current Enterprise Value is ¥8,193.3 Mil.
Shanghai Yizhong Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥78.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Yizhong Pharmaceutical Co (SHSE:688091) has a EV-to-EBITDA of 104.57 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Yizhong Pharmaceutical Co. This is 26% above median its historical median of 82.80. According to the industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #719 out of 745 companies in the Drug Manufacturers industry, placing it in the top 96.5%.
Is Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA too high?
Shanghai Yizhong Pharmaceutical Co's current EV-to-EBITDA of 104.57 is 26% above median its 10-year median of 82.80. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Shanghai Yizhong Pharmaceutical Co's value of 104.57 is 732.6% above this industry median. Based on the distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #719 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Yizhong Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Yizhong Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Yizhong Pharmaceutical Co ranks #719 out of 745 companies for EV-to-EBITDA. This places Shanghai Yizhong Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. Shanghai Yizhong Pharmaceutical Co's value of 104.57 is 732.6% above this benchmark. While the company's 10-year median is 82.80 vs. the industry median of 12.56, Shanghai Yizhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Yizhong Pharmaceutical Co's current EV-to-EBITDA of 104.57 is 732.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Yizhong Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Yizhong Pharmaceutical Co's current EV-to-EBITDA is 104.57, which is 26% above median its own 10-year median of 82.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Yizhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co (SHSE:688091) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥47.33, compared to a current price of ¥41.65 — trading 12% below its estimated fair value. The current EV-to-EBITDA is 104.57, which is 26% above median its 10-year median of 82.80 and 732.6% above the Drug Manufacturers industry median of 12.56. Shanghai Yizhong Pharmaceutical Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Yizhong Pharmaceutical Co (SHSE:688091), the current EV-to-EBITDA is 104.57 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Yizhong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥41.65 is trading 12% below its estimated GF Value™ of ¥47.33.
GuruFocus considers Shanghai Yizhong Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688091:
EV-to-EBITDA: 104.57 (26% above median its 10-year median of 82.80)
GF Value™: ¥47.33 vs. price of ¥41.65 (12% below fair value)
Industry Position: 732.6% above the Drug Manufacturers median (#719 of 745)
No single metric tells the full story. See the SHSE:688091 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
57GF Score
Get the complete analysis for SHSE:688091
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688091 has been successfully added to your 
